Abstract
New treatments for patients with Waldenstrom's macroglobulinemia (WM) have necessited the development of prognostic indices. Using a sample of 92 patients with refractory or relapsing WM treated in a randomized trial, we show that Morel's prognostic scoring system for patients at diagnosis is also effective in patients with advanced disease.
Publication types
-
Letter
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Antineoplastic Agents / pharmacology
-
Cohort Studies
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Therapy, Combination
-
Humans
-
Male
-
Middle Aged
-
Multivariate Analysis
-
Prednisone / administration & dosage
-
Prognosis
-
Time Factors
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
-
Waldenstrom Macroglobulinemia / diagnosis*
-
Waldenstrom Macroglobulinemia / therapy*
Substances
-
Antineoplastic Agents
-
Doxorubicin
-
Cyclophosphamide
-
Vidarabine
-
fludarabine
-
Prednisone